The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis

The Role of Anti-Angiogenics in Pre-Treated Metastatic <i>BRAF</i>-Mutant Colorectal Cancer: A Pooled Analysis

<i>Background</i>. FOLFOXIRI plus Bevacizumab is one of the most frequently used first-line treatments for patients with <i>BRAF</i>-mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate the impac...

Full description

Bibliographic Details
Main Authors: Fabio Gelsomino, Andrea Casadei-Gardini, Daniele Rossini, Alessandra Boccaccino, Gianluca Masi, Chiara Cremolini, Andrea Spallanzani, Massimo Giuseppe Viola, Ingrid Garajovà, Massimiliano Salati, Maria Teresa Elia, Francesco Caputo, Chiara Santini, Alfredo Falcone, Stefano Cascinu, Emiliano Tamburini
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
colorectal cancer
BRAF mutation
anti-angiogenics
chemotherapy
MSI-H
Online Access:https://www.mdpi.com/2072-6694/12/4/1022

Similar Items

Similar Items